Quick Win by the Algorithm: Amgen partnership looks to provide significant upside for ARWR in 2018

Quick Win by the Algorithm

 

 

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreement with Amgen, Inc. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Shares of ARWR, a preclinical-stage biotech developing therapies that silence troublesome genes, spiked after the presentations at this year’s JP Morgan Healthcare Conference. Held between the 8th and 11th of January 2018, ARWR presented its forward looking expectations, pipeline, Amgen collaboration and pre-clinical stage medicines.

Amgen (Nasdaq:AMGN), highlighted an Arrowhead Pharmaceuticals molecule, AMG-890, as a foundation to the biotech’s ongoing expansion into cardiovascular disease. This prompted excitement amongst ARWR investors and was similarly reflected within the price rise.

ARWR has announced that Amgen has an exclusive license to the atherosclerosis candidate, and an option to develop another against an undisclosed target. If a candidate succeeds, ARWR will receive loyalty rights, in particular, $35 million in up-front cash and a $21.5 million equity investment. Potential payments could raise the value of the deal as high as $673.5 million.

On January 9th, 2018, I Know First issued a bullish 14 day forecast for Arrowhead Pharmaceuticals. Inc. (NASDAQ: ARWR). The forecast showed a signal of 23.62 and a predictability of 0.15. In accordance with the forecast, ARWR’s stock returned 38.02% over this period, solidifying another quick win by the I Know First algorithm.

Current I Know First subscribers received this bullish ARWR forecast on January 9th, 2018

How to read the I Know First Forecast

Disclaimer

Before making any trading decisions, consult the latest forecast as the algorithm updates predictions daily. You can use the algorithm for intra-day trading. The predictability tends to become stronger with forecasts over longer time-horizons such as the 1-month, 3-month and 1-year forecasts.